Type
Buy
Instrument
BIOCON
Entry Price
₹381
Price@Trade
₹381
Target Price
₹405
Stop Price
₹370
Valid Till
May 17, 2021 3:20 AM
Margin
₹19,050 approx for 50 Qty
Status
Active
FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
BIOCON
380.7
+1 (0.26%)
Updated 03:28 07/05 IST
BIOCON Buy or Sell - FrontPage Forums
19 Users have submitted 23 trade ideas of Rs. 3,948,239.42 for BIOCON
Disclaimer100% Bullish
0% Bearish
BIOCON Buy or Sell - Brokerage Reports
No. of reports in last year
8
No. of analysts
4
Average Consensus Forecast
417.62
Consensus Potential
3.57%
BIOCON Ratings
Long term BIOCON rating by FrontPage users
- ★★
- ★★
- ★★
- ★★
- ★★
4.4/5 (7 Ratings)
Find answers to all your questions on live BIOCON message board: Is BIOCON buy or sell? Should I buy BIOCON shares? Why are BIOCON shares falling? Should I invest in BIOCON stock?
- Home
- BIOCON Forum
BIOCON Share Price Discussion
A
Reputation: 216 • Yesterday 4:10 AM
Biocon Scrip Case: SEBI Imposes Penalty on 6 Entities, Bans Them from Trading for 2 Years
Market regulator the Securities and Exchange Board of India (SEBI) has barred six entities from the markets for two years for indulging in manipulative trading in the shares of Biocon Ltd in the cash market.
Market regulator the Securities and Exchange Board of India (SEBI) has barred six entities from the markets for two years for indulging in manipulative trading in the shares of Biocon Ltd in the cash market.
Moneylife NEWS & VIEWS
Like
Reply
N
Reputation: 13,650 • May 7 4:26 AM
Biocon shares up 0.5% as Nifty gains
A total of 35,213 shares changed hands on the counter till 10:51AM (IST).
A total of 35,213 shares changed hands on the counter till 10:51AM (IST).
The Economic Times
Like
Reply
N
Reputation: 13,650 • May 6 6:01 AM
Biocon shares drop 0.51% as Sensex rises
The stock quoted a 52-week high of Rs 487.7 and a 52-week low of Rs 320.9.
The stock quoted a 52-week high of Rs 487.7 and a 52-week low of Rs 320.9.
The Economic Times
Like
Reply
N
Reputation: 13,650 • May 6 5:41 AM
Second wave of COVID-19 has hit India 'like a tsunami': Kiran Mazumdar Shaw
“This time around the second wave has hit like a tsunami. And the unfortunate part is it has not spared any part of our country,” Mazumdar said during a virtual panel discussion on global vaccine equity organised by One Share World.
“This time around the second wave has hit like a tsunami. And the unfortunate part is it has not spared any part of our country,” Mazumdar said during a virtual panel discussion on global vaccine equity organised by One Share World.
The Economic Times
Like
Reply
H
Reputation: 16 • May 5 3:08 AM
Biocon🔥
Buy 380
SL 370
Target 390,395,400
Always follow Risk management and psychological stability when taking trade.
Being Disciplined is the only thing that pays off in the securities market in long run.
This is only for education purpose, contact your financial advisor befo...
Read more...
1
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
- keyboard_arrow_down
BIOCON Share Price - Technicals
- NewsBotMay 7 4:26 AMBiocon shares up 0.5% as Nifty gainsThe Economic TimesNewsBotMay 6 6:01 AMBiocon shares drop 0.51% as Sensex risesThe Economic TimesNewsBotMay 6 5:41 AMSecond wave of COVID-19 has hit India 'like a tsunami': Kiran Mazumdar ShawThe Economic TimesNewsBotMay 5 7:01 AM
Biocon shares gain 1.71% as Sensex risesThe Economic TimesNewsBotMay 4 6:46 AM
Biocon shares down 0.44% as Nifty dropsThe Economic TimesNewsBotMay 3 5:36 AM
Share price of Biocon falls as Nifty weakensThe Economic TimesNewsBotMay 2 3:46 AM
Biocon Biologics provided 7,000 doses of Itolizumab in AprilThe Economic TimesNewsBotApr 30 7:46 AM
Biocon shares down 3.16% as Sensex fallsThe Economic TimesNewsBotApr 29 10:36 AM
Billion dollar target for biologics biz by FY22 unrealistic, but we would soon return to high growth trajectory: Kiran Mazumdar ShawThe Economic TimesNewsBotApr 29 4:31 AM
Biocon shares gain 1.32% as Sensex fallsThe Economic Times
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.